SF3B1 and B-cell chronic lymphocytic leukemia: To determine whether H3B-8800 and Tem combination treatment could be translated to human CLL, we exposed CLL patient samples with both del(13q) and SF3B1 mutations (n = 3) or without these 2 lesions (n = 3) or with del(13q) alone (n = 3), or with SF3B1 mutations alone (n = 3) to a series of concentrations of Tem (0.1 nM to 10 μM) combined with H3B-8800 (0.1 mM) in vitro for 24 hours.